EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access

Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis

Burhan Gunawan, Heri Nugroho, Roy Panusuan Sibarani

touchREVIEWS in Endocrinology · 28.10.2025 · 21 (2)

DOI: 10.17925/ee.2025.21.2.5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift touchREVIEWS in Endocrinology, online erschienen am 28.10.2025. Verfasst von Burhan Gunawan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Initiative Indonesia, Sumber Waras Hospital, West Jakarta, Indonesia. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) can improve metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with type 2 diabetes (T2D). However, comprehensive research comparing dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA, glucagon receptor (GCGR) agonist/GLP-1RA and GLP-1RA is limited. This meta-analysis aimed to summarize the current evidence for the efficacy and safety of dual GLP/GIP-1RA, GCGR/GLP-1RA and GIP-1RA for these individuals. PubMed, Web of Science, Scopus and the Cochrane database were searched for randomized controlled trials that explore the efficacy of dual GIP/GLP-1RA, GCGR/GLP-1RA or GLP-1Ras for MASLD and T2D. The outcomes were the reversal of liver fibrosis degree and liver fat content (LFC) calculated using magnetic resonance imaging scan. The random-effects model was used to calculate the mean difference (MD) and odds ratio (OR) with a 95% confidence interval (CI). Thirteen studies with a total pooled sample of 1,552 individuals were included in the study. Dual GIP/GLP-1RA, GCGR/GLP-1RA and GLP-1RA were significantly superior in reversing the liver fibrosis degree (OR 3.72; 95% CI: 2.72, 5.09; p

Schlagwörter

Stichwörter der Autor:innen

Glucagon-like peptide 1glucagon receptorglucose-dependent insulinotropic peptideliver steatosistype 2 diabetes

Autor:innen und Institutionen

  • Diabetes Initiative Indonesia, Sumber Waras Hospital, West Jakarta, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Central Java, Indonesia.
  • EMC Sentul Hospital, Bogor, Indonesia.

Zitieren

APA

Gunawan, B., Nugroho, H., & Sibarani, R. P. (2025). Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis. touchREVIEWS in Endocrinology, 21(2). https://doi.org/10.17925/ee.2025.21.2.5

Vancouver

Gunawan B, Nugroho H, Sibarani RP. Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis. touchREVIEWS in Endocrinology. 2025;21(2). doi:10.17925/ee.2025.21.2.5

BibTeX
@article{Gunawan2025,
  author = {Gunawan, Burhan and Nugroho, Heri and Sibarani, Roy Panusuan},
  title = {Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis},
  journal = {touchREVIEWS in Endocrinology},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.17925/ee.2025.21.2.5}
}
Kostenlos starten →